Reported 2 days ago
In response to a looming 100% tariff on imported drugs, global pharmaceutical companies are rapidly increasing their U.S. manufacturing and investments. Major firms like Pfizer, Eli Lilly, and Johnson & Johnson have announced multi-billion dollar commitments to bolster domestic production and R&D, seeking to mitigate supply chain risks and secure tariff exemptions. Initiatives include new manufacturing facilities, technology transfers, and expanded inventory management, with companies like AstraZeneca and Roche also pledging significant investments in U.S. operations.
Source: YAHOO